Stay updated with breaking news from Nasdaq Phvs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharvaris (NASDAQ:PHVS – Get Rating) shares gapped down before the market opened on Friday . The stock had previously closed at $22.52, but opened at $21.45. Pharvaris shares last traded at $20.65, with a volume of 330 shares. A number of brokerages have recently issued reports on PHVS. SVB Leerink lowered their target price on […]
Pharvaris (NASDAQ:PHVS – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $21.23, but opened at $21.86. Pharvaris shares last traded at $21.86, with a volume of 1 shares. PHVS has been the subject of several analyst reports. Morgan Stanley cut their price target on shares of […]
Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...
Pharvaris (NASDAQ:PHVS – Get Rating) had its target price cut by investment analysts at Morgan Stanley to $40.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 127.92% from […]
Zacks Investment Research lowered shares of Pharvaris (NASDAQ:PHVS – Get Rating) from a buy rating to a hold rating in a report issued on Saturday morning, Zacks.com reports. According to Zacks, “Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor […]